CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 60 target
Drug / intervention
Mesenchymal stem cellsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01763086
NCT01763086Phase 2Unknown
CompareCT.gov

Mesenchymal Stem Cells From Third-party Donors for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation

Nanfang Hospital, Southern Medical University·interventional·Posted Jan 8, 2013·Updated Jan 16, 2013

In Brief

A Phase 2 clinical trial evaluating Mesenchymal stem cells for Stem Cell Transplantation, Hematopoietic and 3 related conditions. Targeting 60 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the utility of treating patients experiencing poor graft function after allogeneic hematopoietic stem cell transplantation with ex-vivo-expanded BM-drived mesenchymal stem cells from third-party donors. Our first objective was to evaluate the effect of such treatment on poor graft function, and second object was to investigate the safety of such treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStem Cell Transplantation, Hematopoietic, Mesenchymal Stem Cells, Poor Graft Function, Hematological Diseases
CountriesChina
CollaboratorsPeking University People's Hospital, Sun Yat-sen University, Guangdong Provincial People's Hospital, Guangzhou General Hospital of Guangzhou Military Command, Southern Medical University, China, Third Affiliated Hospital, Sun Yat-Sen University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou First People's Hospital, Zhongshan People's Hospital, Guangdong, China

Timeline

Phase 2UnknownOverdue
20132014201520162017201820192020202120222023202420252026
First PostedJan 8, 2013
Enrollment StartJan 1, 2013
Primary CompletionJan 1, 2015
Study CompletionJan 1, 2016
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 13.5 years ago

Interventions

Mesenchymal stem cellsbiological

Mesenchymal stem cells will be intravenously infused via a central venous catheter,at a dose of 1×10\^6 cells/kg, over 15 min. The vital signs of all patients will be closely monitored during and for 24h after MSCs administration. If the NEU and PLT levels do not attain the completely response(CR)standards within 14d, a second course of MSCs treatment will be given.